Summary

Overview
The Global Voice Prosthesis Devices Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX% during the forecast period 2023-2030.
Medical devices called voice prosthesis devices assist people who have had laryngectomy surgeries in regaining their speech. A laryngectomy is a surgical surgery in which the larynx (voice box) is removed. This is frequently done in response to cancer or other larynx-related medical issues. Patients who have their larynx removed lose their natural vocal cords, making it hard for them to speak. Devices for voice prostheses are crucial in offering a substitute for vocalization.
Over time, technological developments have enhanced the functionality and design of vocal prosthesis devices, improving the outcomes for laryngectomy patients. With the aid of a speech-language pathologist (SLP), speech therapy is necessary to learn how to utilize a vocal prosthesis efficiently. To improve their speech and communication abilities using their device, patients engage with an SLP. Devices used for voice prostheses need routine care, including cleaning and replacement due to wear and tear.
Market Dynamics: Drivers
The Increasing Focus Towards Voice Prosthesis Devices
The development of adequate preventative and diagnostic methods, particularly in high-risk populations, is crucial for the prognosis of laryngeal cancer, an important oncological entity. Speech, swallowing, breathing, social relations, and emotional health are all significantly impacted by total laryngectomy, which also has an adverse effect on quality of life. Esophageal speech (ES) and tracheoesophageal speech (TES) are the two primary rehabilitation methods used with complete laryngectomy patients. In contrast to TES, which involves surgically implanting a vocal prosthesis that permits air from the lungs to be directed via the prosthesis into the esophagus to make sound, ES uses the pharyngoesophageal segment to produce sound.
Achieving regular hands-free speech with an automated speaking valve (ASV) is the ultimate goal of speech therapy after a laryngectomy. The ASV automatically closes during tracheoesophageal speaking, negating the need to use a finger or hand to occlude the tracheostoma. Because the patient cannot point with his finger at his stoma when using an ASV, it frees up his hands, enables quick verbal response, and lessens the focus on his impairment.
Inhealth Technologies provides silver oxide placed in two valves of the Blom-Singer Dual Valve Indwelling Voice Prosthesis as a material preservative. The secondary speaking valve is designed to function even if the primary valve fails, helping to stop fluid leaking. Standard or large tracheal/esophageal flanges are available for the Blom-Singer Dual Valve Voice Prosthesis. includes insertion/cleaning equipment and a non-sterile vocal prosthesis for use in secondary or replacement TEP treatments.
Limited Awareness ans Accesibility
One big barrier is patients' and healthcare professionals' ignorance about vocal prosthetic equipment. Accessibility to cutting-edge technology and specialist care also be restricted in some areas. Particularly for patients without adequate insurance coverage or in areas with scarce healthcare resources, high costs connected with vocal prosthesis devices and related medical procedures can be a substantial barrier. It takes specialist speech rehabilitation, which can be time-consuming and difficult for some patients, to learn to utilize voice prosthesis devices efficiently. This option may not be chosen by patients because of its intricacy.
Segment Analysis
The global voice prosthesis devices market is segmented based on product type, end-user, and region.
The in-dwelling voice prosthesis devices segment accounted for approximately 45.4% of the market share
When a person has had their larynx (voice box) removed during a laryngectomy treatment, they will utilize indwelling voice prosthesis devices, also known as indwelling tracheoesophageal voice prostheses (TVP). In order to improve speech and communication for laryngectomy patients, these devices are surgically placed.
Patients with laryngeal malignancies who have had laryngectomy may benefit from voice prosthesis (VPs), which are indwelling silicone valves used for speech therapy. A significant issue is the microbial biofilm buildup on VPs, which need frequent replacement and raises the risk of pneumonia and chest infections.
Microbial development is encouraged in the esophagus, where they are exposed to food, saliva, liquids, humidity, and temperatures around 37 °C. The inclusion of silver oxide (Blom Singer Advantage) and Teflon-like fluoroplastic (Provox ActiValve) into the VPs material to inhibit microbial colonization are just two strategies that have been suggested to lengthen the lifespan of the VPs.
Geographical Penetration
North America accounted for approximately 41.2% of the market share
North America has been a dominant force in the global voice prosthesis devices market. The most recent projections from the American Cancer Society for the number of new cases of laryngeal cancer in the United States in 2023 are 12,380 (9,900 in men and 2,480 in women). 750 women and 3,820 men will pass away from laryngeal cancer. About 35% of laryngeal malignancies develop above the vocal cords in the supraglottic region, while 60% begin in the glottis (the region containing the vocal cords).
A relatively tiny percentage of those who are diagnosed with laryngeal cancer are under the age of 55. Laryngeal cancer diagnoses typically occur in adults 66 and older.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global voice prosthesis devices market. The pandemic affected the manufacturing and distribution of medical goods, especially voice prosthesis, by upsetting worldwide supply networks. This might have caused brief shortages and delays in the availability of devices.
Numerous healthcare resources were diverted to deal with the pandemic's immediate crisis, which can have an impact on elective procedures and rehabilitation plans, particularly those using vocal prosthetic devices. During the pandemic, patients had reluctant to have elective surgery, which might have decreased the number of laryngectomy procedures and consequently the demand for voice prosthetic devices.
By Product Type
• Non-dwelling Voice Prosthesis Devices
• In-dwelling Voice Prosthesis Devices
By End-user
• Hospitals
• Clinics
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include F. Hoffmann-La Roche Ltd., Sanofi, Novartis AG, Regeneron Pharmaceuticals, ICU Medical Inc., HEIMOMED Heinze, Atos Medical, and Servona Acclarent Inc.
Why Purchase the Report?
• To visualize the global voice prosthesis devices market segmentation based on product type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of voice prosthesis devices market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global voice prosthesis devices market report would provide approximately 46 tables, 53 figures, and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents